Actualités Novartis Ag - 0K9E | Actions London Stock Exchange

NOVARTIS AG CHF0.50(REGD) Novartis Delivered Strong Sales Growth, Margin Expansion And Breakthrough Innovation Launching Five...

N -- Full year net sales for continuing operations1 up 9% (cc2, +6% USD): -- Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6...

NOVARTIS AG CHF0.50(REGD) Novartis Erzielt 2019 Ein Starkes Umsatzwachstum, Margen-steigerungen Und Bahnbrechende Innovatione...

N -- Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): -- Die Geschäftseinheit...

NOVARTIS AG CHF0.50(REGD) Novartis A Réalisé En 2019 Une Forte Croissance De Son Chiffre D'affaires, Une Augmentation De Sa...

N -- Hausse du chiffre d'affaires net des activités poursuivies1 de 9% sur l'exercice entier (tcc2, +6% USD): -- Pharmaceuticals:...

NOVARTIS AG CHF0.50(REGD) Novartis Completes Tender Offer For All Outstanding Shares Of The Medicines Company

N Basel, January 6, 2020 -- Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced...

NOVARTIS AG CHF0.50(REGD) Novartis Provides Update On Luster Phase Iii Studies In Patients With Uncontrolled Gina 4/5 Asthma

N -- Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication -- Fevipiprant was...

NOVARTIS AG CHF0.50(REGD) Novartis Tender Offer For The Medicines Company Commences

N Basel, December 5, 2019 -- Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Medusa...

NOVARTIS AG CHF0.50(REGD) Novartis To Acquire The Medicines Company For Usd 9.7 Bn, Adding Inclisiran, A Potentially Transfor...

N -- Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia...

NOVARTIS AG CHF0.50(REGD) New Novartis Medicine Adakveo(R) (crizanlizumab) Approved By Fda To Reduce Frequency Of Pain Crises...

N -- Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 -- Adakveo reduced the annual rate...

NOVARTIS AG CHF0.50(REGD) Novartis Cosentyx(R) Shows Encouraging Results Versus Humira(R)* From First-of-its-kind Head-to-hea...

N -- Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing...

NOVARTIS AG CHF0.50(REGD) Novartis Announces Avxs-101 Intrathecal Study Update

N -- FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study...

NOVARTIS AG CHF0.50(REGD) Novartis Delivered Another Strong Quarter With Double Digit Sales Growth And Core1 Margin Expansion...

N -- Continuing operations2 net sales up 13% (cc1, +10% USD) driven by: -- Cosentyx sales of USD 937 million (+27% cc), with strong demand across...

NOVARTIS AG CHF0.50(REGD) Novartis, Encore Un Fort Trimestre: Croissance à Deux Chiffres Des Ventes Et Expansion De La Marge...

N -- Chiffre d'affaires net des activités poursuivies2 en hausse de 13% (tcc1, +10% USD) soutenu par: -- Cosentyx: USD 937 millions...

NOVARTIS AG CHF0.50(REGD) Novartis Verzeichnet Ein Weiteres Starkes Quartal Mit Zweistelligem Umsatz-wachstum Und Höherer Ke...

N -- Der Nettoumsatz der fortzuführenden Geschäftsbereiche2 steigt aufgrund folgender Beiträge um 13% (kWk1, +10% USD): -- Cosentyx...

NOVARTIS AG CHF0.50(REGD) Novartis Receives Fda Approval For Beovu(R), Offering Wet Amd Patients Vision Gains And Greater Flu...

N -- In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one...

NOVARTIS AG CHF0.50(REGD) Novartis Positive 52-week Prevent Data Confirm Cosentyx(R) Efficacy In Addressing Entire Axspa Spec...

N -- Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novartis Ag (0K9E)

Votre Hub pour des idées et discussions en direct en temps réel

0K9E Actualités

NOVARTIS AG CHF0.50(REGD) Novartis Delivered Strong Sales Growth, Margin Expansion And Breakthrough Innovation Launching Five...

NOVARTIS AG CHF0.50(REGD) Novartis Erzielt 2019 Ein Starkes Umsatzwachstum, Margen-steigerungen Und Bahnbrechende Innovatione...

NOVARTIS AG CHF0.50(REGD) Novartis A Réalisé En 2019 Une Forte Croissance De Son Chiffre D'affaires, Une Augmentation De Sa...

NOVARTIS AG CHF0.50(REGD) Novartis Completes Tender Offer For All Outstanding Shares Of The Medicines Company

NOVARTIS AG CHF0.50(REGD) Novartis Provides Update On Luster Phase Iii Studies In Patients With Uncontrolled Gina 4/5 Asthma

NOVARTIS AG CHF0.50(REGD) Novartis Tender Offer For The Medicines Company Commences

NOVARTIS AG CHF0.50(REGD) Novartis To Acquire The Medicines Company For Usd 9.7 Bn, Adding Inclisiran, A Potentially Transfor...

NOVARTIS AG CHF0.50(REGD) New Novartis Medicine Adakveo(R) (crizanlizumab) Approved By Fda To Reduce Frequency Of Pain Crises...

NOVARTIS AG CHF0.50(REGD) Novartis Cosentyx(R) Shows Encouraging Results Versus Humira(R)* From First-of-its-kind Head-to-hea...

NOVARTIS AG CHF0.50(REGD) Novartis Announces Avxs-101 Intrathecal Study Update

NOVARTIS AG CHF0.50(REGD) Novartis Delivered Another Strong Quarter With Double Digit Sales Growth And Core1 Margin Expansion...

NOVARTIS AG CHF0.50(REGD) Novartis, Encore Un Fort Trimestre: Croissance à Deux Chiffres Des Ventes Et Expansion De La Marge...

NOVARTIS AG CHF0.50(REGD) Novartis Verzeichnet Ein Weiteres Starkes Quartal Mit Zweistelligem Umsatz-wachstum Und Höherer Ke...

NOVARTIS AG CHF0.50(REGD) Novartis Receives Fda Approval For Beovu(R), Offering Wet Amd Patients Vision Gains And Greater Flu...

NOVARTIS AG CHF0.50(REGD) Novartis Positive 52-week Prevent Data Confirm Cosentyx(R) Efficacy In Addressing Entire Axspa Spec...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Novartis Ag (0K9E) Actualités

Novartis Ag (0K9E)

Votre Hub pour des idées et discussions en direct en temps réel

0K9E Actualités

NOVARTIS AG CHF0.50(REGD) Novartis Delivered Strong Sales Growth, Margin Expansion And Breakthrough Innovation Launching Five...

NOVARTIS AG CHF0.50(REGD) Novartis Erzielt 2019 Ein Starkes Umsatzwachstum, Margen-steigerungen Und Bahnbrechende Innovatione...

NOVARTIS AG CHF0.50(REGD) Novartis A Réalisé En 2019 Une Forte Croissance De Son Chiffre D'affaires, Une Augmentation De Sa...

NOVARTIS AG CHF0.50(REGD) Novartis Completes Tender Offer For All Outstanding Shares Of The Medicines Company

NOVARTIS AG CHF0.50(REGD) Novartis Provides Update On Luster Phase Iii Studies In Patients With Uncontrolled Gina 4/5 Asthma

NOVARTIS AG CHF0.50(REGD) Novartis Tender Offer For The Medicines Company Commences

NOVARTIS AG CHF0.50(REGD) Novartis To Acquire The Medicines Company For Usd 9.7 Bn, Adding Inclisiran, A Potentially Transfor...

NOVARTIS AG CHF0.50(REGD) New Novartis Medicine Adakveo(R) (crizanlizumab) Approved By Fda To Reduce Frequency Of Pain Crises...

NOVARTIS AG CHF0.50(REGD) Novartis Cosentyx(R) Shows Encouraging Results Versus Humira(R)* From First-of-its-kind Head-to-hea...

NOVARTIS AG CHF0.50(REGD) Novartis Announces Avxs-101 Intrathecal Study Update

NOVARTIS AG CHF0.50(REGD) Novartis Delivered Another Strong Quarter With Double Digit Sales Growth And Core1 Margin Expansion...

NOVARTIS AG CHF0.50(REGD) Novartis, Encore Un Fort Trimestre: Croissance à Deux Chiffres Des Ventes Et Expansion De La Marge...

NOVARTIS AG CHF0.50(REGD) Novartis Verzeichnet Ein Weiteres Starkes Quartal Mit Zweistelligem Umsatz-wachstum Und Höherer Ke...

NOVARTIS AG CHF0.50(REGD) Novartis Receives Fda Approval For Beovu(R), Offering Wet Amd Patients Vision Gains And Greater Flu...

NOVARTIS AG CHF0.50(REGD) Novartis Positive 52-week Prevent Data Confirm Cosentyx(R) Efficacy In Addressing Entire Axspa Spec...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités